Ovarian cancer at early stage is refractory to TGF-β-mediated growth inhibition, whereas at later stage TGF-β promotes tumor proliferation and epithelial-mesenchymal transition (EMT) (22,38–40). Here, TGFB1 is linked to ovarian cancer.